Table 1.
Demographic Characteristics of 393 MSM-Infected Patients with Virologic Failure in ART
| Characteristic | |
|---|---|
| Age (years), n (%) | |
| 15–35 | 246(62.6) |
| 36–50 | 122(31.0) |
| ≥51 | 25(6.4) |
| Age (years), median (IQR) | 32(18–67) |
| Geographical region, n (%) | |
| Pearl River Delta | 334(85.0) |
| Eastern | 15(3.8) |
| Western | 23(5.9) |
| Northern | 21(5.3) |
| Marital status, n (%) | |
| Unmarried | 270(68.7) |
| Married or cohabiting | 97(24.9) |
| Divorced or separated | 26(6.6) |
| Baseline CD4+ T cell count (cells/mm3), n (%) | |
| ≤200 | 243(61.8) |
| >200 | 150(38.2) |
| Baseline CD4+ T cell count (cells/mm3), median (IQR) | 141(1–966) |
| Years from ACT to ART, median (IQR) | 0.10(0.00–8.16) |
| Years from ART to DRT, median (IQR) | 1.42(0.50–8.17) |
| Initial treatment regimen, n (%) | |
| ZDV/D4T+3TC+NVP/EFV | 74(18.8) |
| TDF+3TC+EFV/NVP | 285(72.5) |
| ZDV/TDF+3TC+LPV/r | 34(8.7) |
| DRT viral load (log10 copies/mL), median (IQR) | 4.37(3.00–6.69) |
Abbreviations: ACT, antibody confirmation test; DRT, drug resistance test; ZDV, Zidovudine; D4T, Stavudine; 3TC, Lamivudine; NVP, Nevirapine; EFV, Efavirenz; TDF, Tenofovir disoproxil fumarate; LPV/r, Ritonavir-boosted lopinavir.